osteosarcoma therapeutics - pipeline assessment

1. Osteosarcoma Therapeutics - Pipeline Assessment andMarket Forecasts to 2017

2. The Osteosarcoma Therapeutics Market is Forecast to Show High Growth to 2017 GlobalData estimated the global osteosarcoma therapeutics market to be worth $67m in 2010. The market is forecast to grow at a compound annual growth rate (CAGR) of 6.1% to reach $102m in 2017. This growth is primarily attributed to the presence of promising molecules in the osteosarcoma therapeutics pipeline that are expected to be launched during the forecast period. The Osteosarcoma Therapeutics Market Has High Unmet Need The global osteosarcoma therapeutics market is attractive, with high unmet needs. The unmet need in the market is around 47%, which is valued at approximately $32m. The unmet need arises due to the low safety profile of the marketed drugs. Scope for Entrants with Better Efficacy and Safety Profiles The osteosarcoma therapeutics market is underserved by the currently marketed drugs. This is mainly in terms of safety issues (serious adverse events). The market subsequently provides an opportunity for entrants with better efficacy and safety profiles and novel mechanisms of action. Strong Clinical Pipeline with Several First-in-Class Molecules GlobalData’s analysis found that the osteosarcoma therapeutics pipeline is strong. The pipeline consists of nine molecules in various stages of development. There are eight first-in-class molecules with better safety and efficacy profiles than the

3. currently marketed drugs. There are three molecules in Phase III and three molecules in Phase II of clinical development. Ridaforolimus (MK8669, AP23573, Deforolimus), Mepact (mifamurtide) and Rexin-G are expected to enter to the osteosarcoma therapeutics market during the forecast period. The strong clinical pipeline and high unmet needs are expected to drive the future osteosarcoma therapeutics market. Future Implications for the Osteosarcoma Therapeutics Market Merck & Co., Inc, Millennium Pharmaceuticals, Inc. and Epeius Biotechnologies Corporation are likely to become major players in the future osteosarcoma therapeutics market. This is largely due to the fact that these companies have first-in-class drugs in the late stages of clinical development. GlobalData, the industry analysis specialist, has released its new report, “Osteosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global osteosarcoma market. The report identifies the key trends shaping and driving the global osteosarcoma market. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Osteosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Indu

4. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global osteosarcoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. For further details, please click or add the below link to your browser: http://www.globaldata.com/reportstore/Report.aspx?ID=Osteosarcoma-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Indu Visit our report store: http://www.globaldata.com For more details contact: pressreleases@globaldata.com North America: +1 646 395 5477 Europe: +44 207 753 4299 +44 1204 543 533 Asia Pacific: +91 40 6616 6782